<DOC>
	<DOCNO>NCT03074357</DOCNO>
	<brief_summary>This biomarker study follow-up CPLATFRM2201 . The goal CBASICHR0005 collect another urine sample , interval clinical information , optional DNA sample many original 80 patient possible . This new information transform data obtain PLATFRM2201 cross-section temporal profile , ( ) enable identification biomarkers predictive fast progression , ( b ) satisfy FDA 's recommendation perform `` natural history study '' rare disease .</brief_summary>
	<brief_title>Urine , DNA Clinical Information Collection From Patients With Alport Nephropathy .</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>• Able communicate well investigator , understand comply requirement study able provide write informed consent ( parent legal guardian pediatric adolescent subject ) , must obtain assessment perform . Alport SubjectSpecific Participation CPLATFRM2201 Physically able provide single firstmorning urine sample least 30 mL ( one ounce ) . Alport patient initiated dialysis therapy since participation CPLATFRM2201 exempt criterion may still participate study . Healthy VolunteerSpecific • Male Female Volunteers ( may include healthy sibling Alport patient ) age 5 15 year . Alport SubjectSpecific • None Healthy VolunteerSpecific Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer ; longer require local regulation , limitation participation investigational trial base local regulation . Known history one ( ) hematuria ( gross microscopic ) , ( b ) audiological deficit , ( c ) fix ( nonorthostatic ) proteinuria , ( ) reduce renal filtration function serum creatinine ( Cr ) upper limit normal agespecific reference range , least 2 prior occasion ( serum Cr need measure specifically eligibility ) . Any clinically significant underlying medical condition judge PI .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>